Johnson & Johnson Reaffirms Commitment to Combat Tuberculosis

The Institute of Microbial Technology in India; tuberculosis researcher Koen Andries; a view of the bacteria under a microscope (Source: Johnson & Johnson).

Despite being preventable and curable, tuberculosis (TB) is the world’s deadliest infectious disease, killing 1.5 million people every year—more than HIV/AIDS and malaria combined. Growing drug resistance is compounding this public health challenge. In 2018, there were nearly 500,000 new cases of multidrug-resistant TB (MDR-TB), which does not respond to the two most frequently used first-line TB drugs. Drug-resistant TB now accounts for nearly one-third of all deaths from antimicrobial resistance (AMR).

For nearly 20 years, both in their laboratories and on the ground in countries impacted by TB and MDR-TB, Johnson & Johnson has been supporting global efforts to end TB and combat AMR. In 2012, Johnson & Johnson’s medicine for pulmonary MDR-TB was granted accelerated approval by the United States Food and Drug Administration (U.S. FDA) for use as part of a combination therapy in adults when an effective treatment regimen cannot otherwise be provided.

In September 2018, Johnson & Johnson reaffirmed its commitment to fight again TB by announcing a new 10-year initiative with three pillars:

Expanding access to treatment by offering a non-for-profit price to 130+ low-and middle-income countries, as well as nongovernmental organizations.
Improving case finding and strengthening health systems to reach the thousands of people with undiagnosed TB and MDR-TB and connect them to care.
Accelerating TB research and development (R&D) to discover innovative next-generation treatments.

Read more on Johnson & Johnson’s website.